Argenica Therapeutics (ASX:AGN)
ASX announcement history & article coverage
Transparent by design.
Announcments by Argenica Therapeutics (ASX:AGN) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Webinar
Investor Presentation
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
Argenica completes final FDA safety assay for ARG-007, advancing clinical trial plans
WHO Confirms Xaranetide as INN for ARG-007
WHO Confirms Xaranetide as INN for Argenica's ARG-007
Notification of cessation of securities - AGN
Release of Securities from Voluntary Escrow
IND Application Advanced With Successful Completion of Assay
Argenica clears key FDA genotoxicity test, advancing IND application for ARG-007
Clinical Advisory Committee Established to Advance Phase 2b
Argenica Therapeutics Forms Expert Clinical Advisory Committee to Advance ARG-007 Phase 2b Stroke Trial
Quarterly Activities/Appendix 4C Cash Flow Report
Argenica advances Phase 2b stroke trial prep, secures EMA pediatric waiver, and reports $8M cash
Investor Presentation - Ignite Conference